Fat Content Quantification with US Attenuation Coefficient: Phantom Correlation with MRI Proton Density Fat Fraction
Rongying Chen, Genglin Zhang, Jie Zeng, Yin Zhang, Haixin Chen, Jie Ren, Xin Chen, Manli Wu, Haoming Lin, Ting Zhang · 2025
Read Fat Content Quantification with US Attenuation Coefficient: Phantom Correlation with MRI Proton Density Fat Fraction by Rongying Chen, Genglin Zhang, Jie Zeng, Yin Zhang, Haixin Chen, Jie Ren, Xin Chen, Manli Wu, Haoming Lin, Ting Zhang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12785858.txt.
Introduction
Rongying Chen and nine co-authors published a study in 2025 on measuring body fat with ultrasound, checked against MRI in lab-made models. Fatty organs are usually graded by an MRI measure of fat fraction, the reference standard, but scanners are costly and slow. Ultrasound machines can estimate how strongly tissue absorbs sound, a value that tracks fat content.
Twelve phantoms with fat shares from zero to one hundred percent were scanned by three commercial ultrasound systems and by MRI. The MRI values matched the true fat shares almost perfectly. Ultrasound readings from all three systems agreed with each other and rose in a straight line with fat content, repeatable across operators. The team derived a conversion formula, a step toward cheaper fat checks in ordinary clinics.
Catalog record
| CREATOR | Rongying Chen, Genglin Zhang, Jie Zeng, Yin Zhang, Haixin Chen, Jie Ren, Xin Chen, Manli Wu, Haoming Lin, Ting Zhang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Fat Content Quantification with US Attenuation Coefficient: Phantom Correlation with MRI Proton Density Fat Fraction Authors: Rongying Chen, Genglin Zhang, Jie Zeng, Yin Zhang, Haixin Chen, Jie Ren, Xin Chen, Manli Wu, Haoming Lin, Ting Zhang Published: 2025 ABSTRACT Objective: The aim of this study was to evaluate the consistency and reproducibility of attenuation coefficient (AC) measurements using different commercial ultrasound (US) across via a phantom experiment to investigate the relationship between the AC and MRI-derived proton density fat fraction (MRI-PDFF) values and the conversion equation. Methods: Twelve phantoms containing varying fat proportions (0–100%) were constructed. Phantom ACs were estimated via three US attenuation systems, including attenuation imaging (ATI), ultrasound attenuation analysis (USAT), and the US-guided attenuation parameter (UGAP), along with MRI-PDFF. Agreement among the AC values from the three ultrasonic attenuation systems was evaluated. Linear correlation analysis was used to explore the ACs, fat concentrations of the phantom, and MRI-PDFF measurements, from which a linear conversion formula between the ultrasonic attenuation parameters and the MRI-PDFF was derived. Results: MRI-PDFF and phantom fat concentration measurements appeared with a strong linear correlation (R2 = 0.996, p < 0.001). For the three US attenuation parameters, both inter-operator and intra-operator intraclass correlation coefficients (ICCs) ranged from 0.990 to 0.995 and 0.989 to 0.995, respectively. Bland–Altman analysis revealed no significant differences between the above three (all p > 0.05). Significant linear relationships were demonstrated between ultrasound attenuation parameters and phantom fat concentration (r = 0.938–0.986; all p < 0.001), as well as between ultrasound attenuation parameters and MRI-PDFF values (r = 0.922–0.982; all p < 0.001). A conversion formula (fat proportions ≤ 50%) was derived: US (dB/cm/MHz) = 0.501 + 0.012 MRI-PDFF (%). Conclusions: AC across different commercial ultrasound devices demonstrated significant diagnostic value in fat concentrations that appeared good consistency in measuring phantom fat concentration both between and within groups. The linear relationship between AC and MRI-PDFF enables the application of a conversion formula. 1. Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed metabolic-associated fatty liver disease (MAFLD) or nonalcoholic fatty liver disease (NAFLD), has emerged as the most prevalent chronic liver disease globally, affecting at least 30% of the adult population worldwide [1,2]. In China, the prevalence of NAFLD stands at 29.8%, making it, along with chronic viral hepatitis B or C, alcoholic fatty liver, and drug-induced liver injury, a primary cause of liver cirrhosis and liver cancer, a severe threat to the health of the Chinese population [3]. In 2023, it surpassed chronic hepatitis B as the most common chronic liver disease in China [4]. Steatosis is an initiating factor of MASLD, and the first diagnostic challenge is to accurately detect fat in the liver. Accurate quantification of liver fat content plays an important role in evaluating the risk of progression and liver-related events [2]. Currently, liver biopsy with histopathological examination is the gold standard for diagnosing fatty liver disease. The liver is classified based on the area of hepatocellular steatosis as follows: normal liver tissue S0 < 5%, mild fatty liver S1 5% to <33%, moderate fatty liver S2 33% to <66%, and severe fatty liver S3 ≥ 66%. However, this diagnostic method is invasive and carries risks of bleeding and infection [5,6]. MRI-based techniques for the quantitative assessment of hepatic steatosis have been recognized by multiple guidelines as the most accurate noninvasive method for quantifying liver fat content. Based on hepatic fat volume fraction, the liver can be classified as follows: mild fatty liver (<5%), moderate fatty liver (5% to <17%), and severe fatty liver (17% to <22%) [2]. However, owing to their high cost and venue constraints, both the European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD) guidelines do not recommend the use of MRI-PDFF for screening in routine clinical settings [7,8]. However, conventional ultrasonography is less sensitive for detecting lower degrees of liver fat content and is limited by substantial interobserver variability [9]. Currently, the US attenuation-based fat quantification technique attenuation coefficient (AC) is widely used to evaluate the severity of MASLD and relies on the energy loss of the acoustic signals while traveling through the tissue [2]. The attenuation estimation techniques have been validated by using a phantom with known attenuation values and mathematical simulations [10]. However, AC measurements developed by different manufacturers using various acoustic attenuation measurement systems have inconsistent thresholds for diagnosing and grading fatty liver disease with low degrees of discrimination [11]. Moreover, there is a lack of data regarding the correlation of the ultrasound AC with the MRI-PDFF, which limits the use of the AC in clinical applications. A previous review noted that to better understand the variables affecting US attenuation measurements for the assessment of liver fat content, it is necessary to develop phantoms to compare various vendor systems [12,13]. Current research has introduced various fabrication approaches for multimodal hepatic steatosis phantoms. Madsen et al. incorporated graphite into gelatin–water–alcohol phantoms, where controlled graphite concentrations yield varying values in ultrasound attenuation coefficient measurements [14]. Zhao et al. developed an MRI phantom capable of simultaneous PDFF, R2*, and T1 modulation. They used peanut oil to modulate PDFF, MnCl2 and iron microspheres were used to modulate R2*, and NiCl2 was used to modulate the T1 of water (T1,water) [15] Chmarra et al. Mary developed a cost-effective, simple-to-fabricate multimodal liver phantom compatible with ultrasound, CT, and MRI. The phantom composition consists of six components: candle gel, Sephadex, agarose, glycerol, distilled water, and silicone string [16]. Endsley et al. developed an ultrasound phantom fabrication method that replicates fat vesicle sizes observed in MASLD, facilitating the validation of ultrasound quantification techniques [17]. This study employed ultrasound systems from three different manufacturers to measure attenuation coefficients, followed by consistency analysis of the results. The relationship between ultrasound attenuation coefficients and MRI-PDFF values was analyzed to derive a conversion formula for translating ultrasound-based fat quantification results into percentage values. The study aims to optimize the grading criteria for fatty liver disease in subsequent clinical research. 2. Materials and Methods 2.1. Phantom Preparation The preparation of the fat phantom was improved upon the method described by Bush et al. [18]. A 3% agar powder was used as a gelling agent to create a solid-shaped phantom, while peanut oil served as the fat source. Additionally, 2% potassium sorbate was used as a preservative to extend the shelf life of the phantom, and 2% surfactant was used to emulsify the fat, ensuring a uniform distribution of fat in the water. Furthermore, 3% corn starch was added as a scatterer to increase the base attenuation value of the phantom. The agar powder was used to facilitate phantom formation, while potassium sorbate and corn starch were employed to protect the phantoms from dissection. Both components were mixed to form an aqueous solution. The emulsifier was mixed with peanut oil to obtain an oil solution. The two solutions were mixed in the desired proportions, stirred via a magnetic stirrer, and heated on a hot plate until the mixture appeared uniformly milky white without visible phase separation. The hot plate was turned off, and stirring continued until the solution cooled. The mixture was then poured into pre-prepared containers, which were cylindrical plastic boxes (LOCK&LOCK,